Summary:
In patients with diabetic peripheral neuropathy (DPN), once-daily prolonged-release (PR) pregabalin significantly improved pain management compared to immediate-release (IR) pregabalin, though it was associated with similar adverse effects, including dizziness and somnolence.
| PICO | Description |
|---|---|
| Population | Patients with diabetic peripheral neuropathy (DPN). |
| Intervention | Once-daily prolonged-release (PR) pregabalin. |
| Comparison | Immediate-release (IR) pregabalin. |
| Outcome | Both prolonged-release and immediate-release pregabalin demonstrated similar efficacy in managing pain associated with DPN. Both treatments were associated with comparable side effects, primarily dizziness and somnolence. |
Source: Shilpi Dhawan, et al. “Efficacy and Safety of Once-Daily Prolonged-Release Pregabalin for the Treatment of Patients With Diabetic Peripheral Neuropathy: A Randomized, Double-Blind, Active, and Placebo-Controlled Trial.” Read article here.
